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Abstract
Background The effectiveness of drugs aimed at counteracting cancer cachexia is generally tested in pre-clinical rodent
models, where only the tumour-induced alterations are taken into account, excluding the co-presence of anti-tumour mole-
cules that could worsen the scenario and/or interfere with the treatment.
Methods The aim of the present investigation has been to assess the efficacy of a multifactorial treatment, including
formoterol and megestrol acetate, in cachectic tumour-bearing rats (Yoshida AH-130, a highly cachectic tumour) undergoing
chemotherapy (sorafenib).
Results Treatment of cachectic tumour-bearing rats with sorafenib (90mg/kg) causes an important decrease in tumour cell
content due to both reduced cell proliferation and increased apoptosis. As a consequence, animal survival significantly im-
proves, while cachexia occurrence persists. Multi-factorial treatment using both formoterol and megestrol acetate is highly
effective in preventing muscle wasting and has more powerful effects than the single formoterol administration. In addition,
both physical activity and grip strength are significantly improved as compared with the untreated tumour-bearing animals.
The effects of the multi-factorial treatment include increased food intake (likely due to megestrol acetate) and decreased pro-
tein degradation, as shown by the reduced expression of genes associated with both proteasome and calpain proteolytic
systems.
Conclusions The combination of the two drugs proved to be a promising strategy for treating cancer cachexia in a pre-
clinical setting that better resembles the human condition, thus providing a strong rationale for the use of such combination
in clinical trials involving cachectic cancer patients.
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Introduction
The percentage of cachexia in cancer patients is quite high:
50–80%, and is a useful tool for survival prediction, being
held responsible for more than 20% of the deaths of cancer
patients.1 It is directly responsible for a reduction in physical
activity2 and quality of life, and decreases the efficacy and
outcome of anti-cancer therapy.3,4 In an international
consensus,5 cachexia was defined as a ‘complex metabolic
syndrome associated with underlying illness and character-
ized by loss of muscle with or without loss of fat mass. The
prominent clinical feature of cachexia is weight loss in adults
(corrected for fluid retention) or growth failure in children
(excluding endocrine disorders). Anorexia, inflammation, in-
sulin resistance, and increased muscle protein breakdown
are frequently associated with cachexia. Cachexia is distinct
from starvation, age-related loss of muscle mass, primary de-
pression, malabsorption, and hyperthyroidism, and is associ-
ated with increased morbidity’.5
The loss of weight is due to a reduction of adipose tissue
and muscle, but muscle wasting is the key factor in the cancer
cachexia outcome. Therefore, it determines the survival, and
OR IG INAL ART ICLE
© 2015 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society of Sarcopenia, Cachexia and Wasting Disorders
Journal of Cachexia, Sarcopenia and Muscle 2016; 7: 48–59
Published online 14 May 2015 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/jcsm.12035
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
muscle strength and function, the pillar of the recovery
process.6
There have been many approaches and strategies to treat
the cachexia syndrome, but none of them totally reverses the
weight loss. Those strategies have basically two targets:
counteracting anorexia and neutralizing metabolic distur-
bances.7,8 Many drugs are being developed and tested in clin-
ical trials, but none of these treatments are efficient enough
to be applied in clinical practice.9
The study of cancer cachexia ismainly based on experimental
models (tumour-injected animals) not undergoing the same
anti-tumoural treatments as in humans; therefore, it is difficult
to translate the experimental results to humans: on the one
hand, anti-cancer treatments have side effects that can worsen
cachexia, while on the other hand, the reduction of tumour
mass can mask or delay the appearance of cachexia. Indeed,
in experimental conditions, cachexia occurs within days or a
few weeks after tumour injection, while cancer cachexia in
humans is often a chronic process.
Regarding anti-tumoural therapy, many significant
advances have been made in cancer management with the
development and introduction of new targeted agents,
replacing non-targeted highly toxic chemotherapies. Such
therapies make tumour cells more susceptible, without
substantially increasing toxicity. However, several studies in
humans demonstrated that weight loss associated with
cancer was related to toxicity from treatment, anaemia, and
shorter survival.10,11 Prado et al.10 focused on body composi-
tion as a potential determinant of toxicity in response to
commonly used anti-neoplastic agents. They emphasized
the importance of establishing an adjustment of the anti-
tumoural treatment for lean body mass, due to the relation-
ship between severe skeletal muscle depletion and excess
toxicity during chemotherapy. Indeed, Antoun et al.12
reported that muscle loss was specifically exacerbated by so-
rafenib (Sor) treatment and described it as an adverse effect
of the drug related to asthenia, fatigue, and physical disabil-
ity. Sorafenib is a multikinase inhibitor that showed efficacy
against a wide variety of tumours in pre-clinical models13; it
inhibits cell proliferation by targeting the Raf/MEK/ERK
signalling pathways and exerts an anti-angiogenic effect by
inhibition of tumour angiogenesis through vascular endothe-
lial growth factor receptor (VEGFR) and platelet-derived
growth factor receptor (PDGFR).14,15 It is already approved
in humans for the treatment of advanced hepatocellular car-
cinoma16 and advanced renal cell carcinoma.17 Common side
effects of Sor are cutaneous like hand–foot syndrome or rash
and gastrointestinal like diarrhoea or nausea, as well as
alopecia and fatigue. These side effects limit the patient’s
ability to receive full-dose Sor treatment.18,19
Patient’s ability to tolerate anti-cancer therapy will, in turn,
be affected by their nutritional status preceding treatment,
and it will determine the success of the therapy. So, nutritional
support has to be considered rather as part of the oncological
treatment than as a separated action.20 In spite of this, several
studies demonstrated that nutritional strategies are not
sufficient to reverse the cachectic syndrome. The use of total
parenteral nutrition does not abolish weight loss. This points
out the need that any therapeutic approach based on increas-
ing food intake has to be combined with a pharmacological
strategy to counteract metabolic changes.
One of the drugs most commonly used in cachexia is
megestrol acetate (MA) due to its high efficacy and safety
profile, as confirmed in multiple clinical trials.21,22 Megestrol
acetate is a synthetic derivative of progesterone and has
been described as a potent appetite stimulant and promotes
weight gain. However, this gain had been mainly attributed to
an increased fat mass, not to muscle mass and had no evi-
dences of benefit in terms of quality of life or survival.23,24
The mechanisms of MA responsible for contributing to in-
creased body weight in cachectic patients are not completely
clear, but some studies showed that, in addition to stimulat-
ing appetite, it also had an effect on both metabolic and in-
flammatory mechanisms.25,26 Concerning skeletal muscle,
previous studies performed in our laboratory in experimental
animals showed a clear anabolic effect of MA in skeletal mus-
cle. Thereby, Busquets et al.27 demonstrated that the admin-
istration of MA to tumour-bearing (TB) rats resulted in an
important reversal of the muscle-wasting process, as
reflected by individual muscle weights. The mechanism for
this effect seems to be, at least, partially explained by the
ability of the drug to block the enhanced proteolysis associ-
ated with muscle wasting during cancer cachexia. In fact,
the drug also acted to be improving appetite, and enhancing
physical performance and muscle strength. In another study,
Toledo et al.28 observed that administration of MA to cachec-
tic TB rats caused increased incorporation of orally adminis-
tered labelled 14C-leucine into muscle protein, without
altering the in vivo rate of the amino acid oxidation, sugges-
ting that MA treatment is able to increase protein synthesis
during cancer cachexia.
With regard to finding a pharmacological strategy to coun-
teract metabolic changes, our laboratory introduced the use
of formoterol (F)—a highly potent β2-adrenoceptor-selective
agonist—as a possible drug for the treatment of cachexia.29
The administration of beta-adrenergic agonists had been re-
lated with hypertrophy of skeletal muscles.30–33 Formoterol
combines the clinical advantages of the rapid onset with
the duration of the action, and it is currently in use in humans
for the treatment of bronchospasm associated with
asthma.34 In animal models, data from our laboratory dem-
onstrated that F had important anti-cachectic effects.29 The
mode of action of this drug is based on its ability to prevent
muscle wasting by inhibiting proteolysis and apoptosis in
skeletal muscle. Thereby, F decreased the activation of the
ubiquitin-dependent proteolytic system, the main mechanism
activated in muscle-wasting conditions, and decreased
muscle apoptosis in TB animals.29,35 The anti-wasting effects
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of the drug were also observed in terms of total physical
activity and grip force, thus resulting in an improvement in
physical performance in cachectic TB rats.36
Bearing all this in mind, the aim of the present investiga-
tion was to assess the efficacy of a multi-factorial treatment,




Five-week-old male Wistar rats (Harlan, Barcelona, Spain)
were housed in individual cages and maintained at a constant
temperature of 22 ± 2°C with a regular light–dark cycle (light
Figure 1 Effects of sorafenib on tumour cell cycle status and content in rats bearing the Yoshida AH-130 ascites hepatoma. (A) Cytometric analysis of
the cell cycle distribution of AH-130 cells harvested every other day in both untreated and sorafenib-treated TB rats. A mixed model with repeated
measures (factor days) was used to test the differences between sorafenib-treated and untreated rats over time. A first-order autoregressive covari-
ance structure AR(1) was chosen, according to AIC (Akaike Information Criterion) and BIC (Bayesian Information Criterion). Significant differences
detected between treatments along the days in all phases (G0/G1, S, G2/M, and apoptosis results in Table S2). The average values of population per-
centages at G0/G1, S, G2/M, and apoptosis phases are shown as mean ± standard error from five animals per group. Pairwise comparisons for each
day, significant differences noted as: *,P< 0.05; **, P< 0.01; ***, P< 0.001. (B) Tumour cell content was assessed on day 10 after tumour inocula-
tion. Results are mean ± standard error for eight animals per group. T, tumour-bearing rats; T + S, treated with sorafenib; T + F, treated with
formoterol; T + F + S, treated with both formoterol and sorafenib. Statistical significance of the results by two-way analysis of variance: sorafenib
treatment (P< 0.001), formoterol treatment (P = 0.86), and non-significant interaction between factors (P = 0.64).
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from 8 00 a.m. to 8 00 p.m.) and free access to food and wa-
ter. Experimental cachexia was obtained through i.p. injection
of 108 AH-130 Yoshida ascites hepatoma cells obtained from
exponential tumours as described previously.37 The food in-
take was measured daily. The Bioethical Committee of the
University of Barcelona approved the experimental protocol.
All animal manipulations were made in accordance with the
European Community guidelines for the use of laboratory
animals.38
Experimental design
Four distinct experiments were performed in order to test
the following : (i) the action of anti-tumour drug (Sor) on
Yoshida AH-130 ascites hepatoma cells; (ii) the effectiveness
of the anti-cachectic agent F in TB rats either receiving che-
motherapy (Sor) or not; (iii) the comparison of the survival
of the untreated with Sor-treated TB rats; and (iv) the effec-
tiveness of combined chronic (20 days) administration of F
and MA against cachexia in Sor-treated TB rats.
Experiment I: TB animals were divided into two groups, un-
treated and treated daily with Sor (90mg/kg body weight,
intragastrically (i.g.), from day two after tumour injection).
On days 3, 5, 7, 9, and 11, 100μL of ascites was extracted
from each animal, and cells were analysed by flow cytom-
etry (see below).
Experiment II: the animals were divided into two groups,
namely controls (C) and TB. Both groups were further di-
vided into four subgroups: untreated (vehicle administered),
treated with F (0.3mg/kg body weight, subcutaneous (s.c.),
daily), treated with Sor (90mg/kg body weight, intragastri-
cally (i.g.), daily from day two after tumour injection), and
treated with both drugs. Ten days after tumour transplanta-
tion, the animals were weighted and anaesthetized with an
i.p. injection of ketamine/xylazine mixture (3:1) (Imalgene®
and Rompun®, respectively). Tumour volume and total cell
number were assessed at the day of sacrifice. Tissues were
rapidly excised, weighted, and frozen in liquid nitrogen.
Experiment III: TB animals were divided into two groups,
untreated and treated with Sor (see above). The untreated
group was administered with the corresponding volume of
solvent. The treatment was stopped at day 20 after
tumour inoculation in order to observe tumour relapse.
Experiment IV: the animals were divided into four groups,
one C group (untreated and non-TB) and three TB groups.
The latter three groups were treated from day two after
tumour inoculation with Sor (see above). As for the anti-
cachectic treatments, one TB group was administered the
vehicle, one treated with F (see above), and the last TB
group was treated with F and MA (100mg/kg body weight,
i.g., daily). The animals were sacrificed 20 days after
tumour injection as previously stated.
Flow cytometry
The DNA distribution/cell cycle analysis was performed in
AH-130 cells obtained from alternate day paracentesis in TB
rats. Briefly, cells were washed in phosphate buffer solution
(PBS), fixed in ice-cold 70% ethanol for at least 30min, incu-
bated at room temperature in PBS containingDNase-free RNase
and propidium iodide at the final concentrations of 0.4mg/mL
Table 1 Effects of formoterol treatment on food intake, body weight, and muscle and adipose weight in sorafenib-treated tumour-bearing rats at
day 10 after tumour inoculation
Parameters
Experimental groups
C(6) C+ S(7) C+ F(7) C+ F+ S(7) T(8) T+ S(8) T+ F(8) T+ F+ S(8)
Food intake 128±2c 119±3b 141±3d 122±2b 88±3a 87± 3a 95±4a 91±3a
FBW 236±3d 224± 4c 247±4e 219± 2c 159±3a 178±6b 163±3a 182± 3b
Muscle weight
GSN 739±12de 696±11c 841±10f 758±14e 519±18a 624±9b 604±19b 701±13cd
Soleus 53±2c 49±1c 59±3d 50± 2c 39±1a 44±2b 44±1b 50±1c
Tibialis 236±3c 228± 5c 279±7d 266±9d 174± 7a 200±3b 202± 5b 228±3c
EDL 56±1c 56±1c 67±1d 65±2d 41±2a 50±1b 49±1b 58±1c
Heart 376± 7d 348± 8c 429±11e 413±12e 263± 3a 292±6b 284±5ab 330±8c
Adipose weight
dWAT 1390± 91d 1292±84cd 1277±99cd 1135± 113c 320±72ab 535±65b 211±51a 373±53ab
eWAT 1332±82c 1208±107c 1115±58d 935±71bc 542± 106a 926±49bc 401±89a 822±59b
BAT 266± 16bc 241±22b 283±14c 238±17b 110±7a 125± 4a 117± 6a 118±8a
Results are mean± standard error for the number of animals indicated in parentheses. Food intake is expressed as g/100 g initial body
weight and refers to the cumulative intake (10 days). FBW, final body weight (without tumour) is expressed as g. Tissue weight is
expressed as mg/100 g of initial body weight. GSN, gastrocnemius muscle; EDL, extensor digitorum longus; dWAT, dorsal white adipose
tissue; eWAT, epididymal white adipose tissue; BAT, brown adipose tissue; C, rats without tumour; T, tumour-bearing rats; C+ S and T+S,
treated with sorafenib; C+ F and T+F, treated with formoterol; C+ F+S and T+ F+S, treated with both formoterol and sorafenib.
Statistical significance of the results by full factorial three-way analysis of variance (fixed factors: tumour, sorafenib treatment, and
formoterol treatment). P-values of all the parameters detailed in Table S1. Statistically significant differences by post hoc Duncan test.
Different superscripts indicate significant differences between groups.
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and 10μg/mL, respectively. Cells were then analysed using a
Beckman Coulter Epics XL flow cytometer. Data were then
analysed with the WinCycle software (Phoenix Flow Systems,
San Diego, CA, USA). The percentage of apoptotic cells was
assessed by evaluating the accumulation of cells having a
<2n DNA content.
Blood haematochemical assays
Plasma albumin, triacylglicerides, glucose, and lactate were
analysed by METROLAB 2300 (RAL S.A., Barcelona, Spain), a
chemistry analyser that is based on the analysis of colorimet-
ric reactions.
Biochemicals
Sorafenib was obtained from GENTAUR (Kampenhout,
Belgium), F was kindly provided by Industriale Chimica s.r.l.
(Saronno, Italy), and MA was obtained from Sigma Chemical
Co. (St. Louis, MO, USA).
RNA isolation and reverse trascription–PCR
Total RNA from the gastrocnemius muscle was extracted by
TriPureTM kit (Roche, Barcelona, Spain), a commercial modifi-
cation of the acid guanidinium isothiocyanate/phenol/chloro-
form method.39 Reverse transcription (RT) reactions were
prepared using by First Strand cDNA Synthesis Kit for RT–PCR
(Roche, Barcelona, Spain) following themanufacturer’s instruc-
tions. Analysis of mRNA levels for the genes from the different
proteolytic systems was performed with primers designed to
detect the following gene products: ubiquitin (FORWARD 5′
GAT CCA GGA CAA GGA GGG C 3′, REVERSE 5′ CAT CTT CCA
GCT GCT TGC CT3′); E2 (FORWARD: 5′ AGG CGA AGA TGG
CGG T 3′; REVERSE 5′ TCA TGC CTG TCC ACC TTG TA 3′); C8 pro-
teasome subunit (FORWARD 5′ AGA CCC CAA CAT GAA ACT GC
3′; REVERSE 5′ AGG TTT GTT GGC AGA TGC TC 3′); C2 protea-
some subunit (FORWARD: 5′ GTTTCCATTGGGATTGTTGG 3′; RE-
VERSE: 5′ TGTTCCATTGGTTCATCAGC 3′); MuRF-1 (FORWARD 5′
TGT CTG GAG GTC GTT TCC G 3′; REVERSE 5′ ATG CCG GTC CAT
GAT CAC TT 3′); Atrogin-1 (FORWARD 5′ CCA TCA GGA GAA
GTG GAT CTA TGT T 3′; REVERSE 5′ GCT TCC CCC AAA GTG
CAG TA 3′); m-calpain (FORWARD 5′ TTG AGC TGC AGA CCA
TC 3′; REVERSE 5′ GCA GCT TGA AAC CTG CTT CT 3′); cathepsin
B (FORWARD 5′ CTG CTG AGG ACC TGC TTA C 3′; REVERSE 5′
CAC AGG GAG GGA TGG TGT A 3′); and hydroxymethylbilane
synthase (FORWARD 5′ TGC CAG AGA AAA GTG CCG TGG G
3′; REVERSE 5′ TGC AGC TCA TCC AGC TTC CGT 3′). To avoid
the detection of possible contamination by genomic DNA,
primers were designed in different exons. The real-time PCR
was performed using a commercial kit (LightCycler TM 480 SYBR
Green I Master, Roche, Barcelona, Spain). The relative amount
of all mRNA was calculated using comparative CT method.
Hydroxymethylbilane synthase mRNA was used as the invari-
ant control for all studies.
Total physical activity
Total physical activity (IR ACTIMETER System and ACTITRAK
software from Panlab, Barcelona) was assessed during the last
24 h prior to the sacrifice of the animals in different experi-
mental groups, using activity sensors that translate individual
changes in the infrared pattern caused by movements of the
animals into arbitrary activity counts.40 For the measurements,
Figure 2 Effects of formoterol on total physical activity and grip force in
sorafenib-treated tumour-bearing rats. Results are mean ± standard
error for seven animals per group in control groups (without tumour)
and eight animals per group in tumour-hosts groups. C, rats without
tumour; T, tumour-bearing rats; C + S and T + S, treated with sorafenib;
C + F and T + F, treated with formoterol; C + F + S and T + F + S, treated
with both formoterol and sorafenib. Statistical significance of the
results by full factorial three-way analysis of variance (fixed factors:
tumour, sorafenib treatment, and formoterol treatment). P-values of
all the parameters are detailed in Table S3. Statistically significant
differences between all groups were assessed by pairwise comparisons
post hoc Duncan test; different superscripts indicate significant differ-
ences between groups.
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animals remained in their home cage. A frame containing an
infrared beam system was placed on the outside of the cage;
this minimized stress to the animals.
Grip-force assessment
Skeletal muscular strength in rats was quantified by the grip-
strength test.40 The grip-strength device (Panlab-Harvard
Figure 3 Survival. Kaplan–Meier survival analysis between untreated tumour-bearing rats and sorafenib-treated tumour-bearing rats (T + Sor).
Sorafenib administration was stopped at day 20 after tumour inoculation (dotted line) in order to observe tumour relapse. Comparison of survival
curves were analysed by log-rank test (Mantel–Cox). The global comparison for the treatments has a P-value< 0.001.
Figure 4 Effects of formoterol and formoterol +megestrol acetate on
tumour cell content in sorafenib-treated tumour-bearing animals. Tumour
cell content was assessed on day 20 after tumour inoculation. Results are
mean ± standarderror for eight animalsper group. T + S, tumour-bearing rats
treated with sorafenib; T + S + F, tumour-bearing rats treated with sorafenib
and formoterol; T + S + F +MA, tumour-bearing rats treated with sorafenib,
formoterol, and megestrol acetate. Statistical analysis of the results by
one-way analysis of variance showed non-significant differences (P = 0.31).
Figure 5 Effects of formoterol and formoterol +megestrol acetate on
food intake in sorafenib-treated tumour-bearing animals. Food intake
is expressed in g/100 g initial body weight and refers to the ingestion
during the period of the experiment prior to sacrifice, which took place
20 days after tumour inoculation. Results are mean ± standard error for
seven to nine animals per group. C, animals without tumour; T + S,
tumour-bearing rats treated with sorafenib; T + S + F, tumour-bearing rats
treated with sorafenib and formoterol; T + S + F +MA, tumour-bearing
rats treated with sorafenib, formoterol, and megestrol acetate. Statistical
significance differences between groups were detected by one-way
analysis of variance (P< 0.001). Pairwise comparisons were performed
by post hoc Duncan test; different superscripts indicate significant
differences between groups.
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Apparatus, Spain) comprised a pull bar connected to an iso-
metric force transducer (dynamometer). Basically, the grip-
strength meter was positioned horizontally, and the rats are
held by the tail and lowered towards the device. The animals
are allowed to grasp the bar and were then pulled backwards
in the horizontal plane. The force applied to the bar just be-
fore it lost grip was recorded as the peak tension. At least
three measurements were taken per rat, and the results were
averaged for analysis. The data are presented as g/g initial
body weight.
Statistical analysis
Average (arithmetic mean) and standard error were calcu-
lated for each studied variable. In Experiment I, a mixed model
with repeated measures (longitudinal design) was performed.
In Experiments II and IV, intergroup differences were evalu-
ated statistically using analysis of variance (ANOVA); Experi-
ment II: three-way ANOVA (fixed factors: tumour, Sor
treatment, and F treatment); and Experiment IV: one-way
ANOVA with four levels. Post hoc pairwise comparisons (Dun-
can test) were performed when appropriated. In Experiment III,
survival curves were computed with the Kaplan–Meier method,
and differences in survival were validated with log-rank test
(Mantel–Cox). All statistical tests were performed using SPSS
version 21.
Results and discussion
The majority of studies involving anti-cachectic therapies are
performed in TB animals not subjected to any anti-tumoural
treatment. This fact may interfere with the translation of
the results to human subjects, since in the clinical practice,
anti-tumoural treatment is given as soon as cancer is diag-
nosed. For this reason in the present study, we adopted a
well-established cachexia model (rats bearing the Yoshida
AH-130 ascites hepatoma) and added the administration of
a new generation anti-tumour drug, Sor.17
The flow cytometry analysis of cell cycle phases in alternate-
day tumour samples (Figure 1) showed that Sor has a bimodal
action; a rapid (3days after the first administration) exit from
the cell cycle (reduced S (synthesis phase) and increased G0
(resting phase)/G1 (Growth 1/Gap 1 phase) was followed by
a strong increase of G2 (pre-mitotic phase)/M (mitosis phase)
arrest and apoptosis, suggesting that Sor is both an inhibitor of
cell proliferation and an inducer of cell death.
Ten days after tumour inoculation, the cellularity in Sor-
treated animals was reduced by 63% (Figure 1B). Formoterol
treatment did not result in any changes of tumour cell con-
tent, as previously described.29 Bearing in mind the strong
anti-tumoural action of Sor, one would expect a consequent
and consistent reduction of cachexia appearance. This was
not the case, since Sor treatment was not free from side
effects, such as hypophagia, even detectable in control
(non-TB) animals (Table 1). However, Sor administration did
not further reduce the food intake observed in TB animals,
likely resulting from the combination of an attenuated
tumour action and the drug-induced hypophagia. In the control
group, the decreased food intake was associated with a reduc-
tion of bodyweight (Table 1). Again, similarly to the food intake,
Sor treatment in TB animals did not worsen the body weight,
possibly because of the decrease of tumour cell content induced
by Sor. The effects of F on body weight were also distinct in
control and TB animals: while F treatment increased the body
weight significantly in the former ones, it did not produce any
changes in the latter ones. Finally, the combination of F with
Sor resulted in a decreased body weight in the control group,
while an increase in the TB animals was observed. Again, this
distinct behaviour may rely on the decreased cell content
promoted by Sor, which possibly compensates the anorexigenic
effects of Sor.
In non-TB rats, Sor induced a significant decrease in gas-
trocnemius (6%) and heart (7%) mass (Table 1). Actually,
Antoun et al.12 described skeletal muscle wasting as an
Table 2 Effects of the combination of formoterol and megestrol acetate treatment in sorafenib-treated tumour-bearing rats on muscle weight at




C (7) T+ S (8) T+ S+ F (8) T+ S+ F+MA (9) P-value
Muscle weight
GSN 1005±24 c 630±19 a 723±33 b 762± 28 b < 0.001
Tibialis 314±6 c 208±5 a 247±12 b 251±8 b < 0.001
Soleus 73±1 d 50±1 a 55±2 b 62±2 c < 0.001
EDL 76±2 c 53±1 a 60±3 b 62± 1 b < 0.001
Diaphragm 474±16 b 371±12 a 342±18 a 513± 23 b < 0.001
Heart 549±23 c 376±16 a 401±14 ab 429± 14 b < 0.001
Results are mean± standard error for the number of animals indicated in parentheses. Muscle weight is expressed as mg/100 g of initial
body weight. GSN, gastrocnemius muscle; EDL, extensor digitorum longus; C, animals without tumour; T+ S, tumour-bearing rats treated
with sorafenib; T+ S+ F, tumour-bearing rats treated with sorafenib and formoterol; T + S+ F+MA, tumour-bearing rats treated with
sorafenib, formoterol, and megestrol acetate. Statistical significance of the results by one-way analysis of variance (ANOVA). Statistically
significant differences by post hoc Duncan test. Different superscripts indicate significant differences between groups.
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adverse effect of Sor treatment. However, it is interesting to re-
mark that Sor treatment did not significantly affect white adi-
pose tissue mass. Therefore, it may be suggested that Sor
side effects are more severe on skeletal muscle rather than
on adipose tissue. As can be observed in Table 1, F treatment
completely reversed the effects of Sor on skeletal muscle, with-
out affecting adipose tissue. Sorafenib treatment in TB rats at-
tenuated skeletal muscle and heart weight loss (Table 1),
probably as a consequence of the reduction in tumour cell con-
tent induced by Sor. The other way round, bearing in mind the
two-third reduction of tumour content, the animals were
frankly cachectic, probably due to the combination of both re-
sidual tumour and Sor action. Consistently, F administration
was able to ameliorate muscle mass in TB animals, either un-
treated (as previously reported36) or Sor-treated.
The different effects on food intake, and body and muscle
weights were compared with physiological parameters such as
physical activity and muscle strength. In Figure 2, TB animals
clearly showed a decrease in both parameters: total physical ac-
tivity and grip strength. Treatment with Sor in healthy rats
caused a reduction in physical activity (16%) and grip strength
(17%). These changes agree with the previous effects of Sor
on muscle weight (Table 1). Notably, Sor treatment, while
prominently reducing the tumour burden, did not affect total
physical activity and actually increased grip strength in TB ani-
mals (Figure 2). On the other hand, F increased both parameters
in the control and TB animals. Remarkably, F administration to
Sor-treated animals induced an even higher increase in physical
activity (29%) and grip strength (33%) as compared with the TB
animals only receiving the anti-tumoural treatment.
In summary, the use of F in Sor-treated animals seems to
be highly effective in preventing muscle wasting and, thus,
facilitating physical activity and, therefore, quality of life even
in the presence of a chemotherapy regimen.
Taking into consideration that Sor treatment was able to
strongly decrease tumour growth, a survival curve was per-
formed (Figure 3). It can be seen that Sor was able to consid-
erably increase survival (log-rank test, P< 0.001). After
20 days (approximately the double survival time of untreated
TB rats), we stopped Sor treatment and observed tumour
relapse, eventually leading to animal death around day 30.
Bearing this in mind, we decided to perform another se-
ries of experiments lasting 20 days following tumour inocula-
tion in order to establish a potential chronic anti-cachectic
protocol able to extend healthy lifespan. This experimental
setting better resembles the human condition, where, after
tumour diagnosis, an anti-cancer treatment is given and, de-
spite the arrest of tumour growth, cachexia appears. At this
time point, Sor-treated TB animals have only a very low re-
sidual tumour cell count, which cannot be assessed easily.
We also incorporated a multi-factorial anti-cachectic treat-
ment by combining F with MA. The rationale behind this
was to provide a drug to compensate the hypophagia in-
duced by Sor. Indeed, MA has been described as an
orexigenic drug, and its use in cancer patients is widely
used.23 In addition, our laboratory described the anabolic
effects of the drug in skeletal muscle.27
As shown in Figure 4, no effects were observed of either F
or MA treatment on tumour cell content. The orexigenic
action of MA can be observed in Figure 5; indeed, while no
effects of F were seen, the combination increased food intake
by 18%, despite being far from a complete recovery. In
Sor-treated TB rats, F administration caused once again a
positive effect on the majority of skeletal muscles studied
Figure 6 Effects of formoterol and formoterol +megestrol acetate on
total physical activity and grip force in sorafenib-treated tumour-bear-
ing animals. Total physical activity was assessed during the last 24 h
prior to sacrifice of the animals on day 20 after tumour inoculation
and was expressed as number of movements and grip force was
assessed before the sacrifice. Results are mean ± standard error for
seven to nine animals per group. C, animals without tumour; T + S,
tumour-bearing rats treated with sorafenib; T + S + F, tumour-bearing rats
treated with sorafenib and formoterol; T + S + F +MA, tumour-bearing
rats treated with sorafenib, formoterol, and megestrol acetate. Statistical
significance between groups detected by one-way analysis of variance
(Total physical activity; P< 0.001; grip strength, P< 0.001). Post hoc
Duncan tests were performed; different superscripts indicate significant
differences between groups.
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(Table 2). Interestingly, the combination of F and MA was
even more effective in the mainly oxidative muscles soleus
and diaphragm, promoting an additional significant increase
(13% for soleus and 50% for diaphragm) as compared with
the animals that were treated only with F.
In relation to physical activity and muscle force, 20 days of
tumour growth (18 of Sor administration) induced a signifi-
cant decrease in both parameters (Figure 6). The combination
of F and MA treatments was successful in significantly in-
creasing both physical activity and grip strength, especially
Figure 7 Effects of formoterol and formoterol +megestrol acetate on albumin and circulating metabolites in sorafenib-treated tumour-bearing
animals on day 20 after tumour inoculation. Results are mean ± standard error for seven to nine animals per group. C, animals without tumour; T + S,
tumour-bearing rats treated with sorafenib; T + S + F, tumour-bearing rats treated with sorafenib and formoterol; T + S + F +MA, tumour-bearing rats
treatedwith sorafenib, formoterol, andmegestrol acetate. One-way analysis of variance denoted statistically significant differences between treatments
(albumin, P = 0.003; glucose, P = 0.008; triglycerides, P< 0.001; lactate, P< 0.001). Post hoc pairwise comparisons (Duncan test) were performed;
different superscripts indicate significant differences between groups.
Table 3 Effects of the combination of formoterol and megestrol acetate treatment on gastrocnemius gene expression in sorafenib-treated tumour-
bearing rats at day 20 after tumour inoculation
Experimental groups ANOVA
Proteolytic system C (6) T+ S (7) T+ S+ F (7) T+ S+MA+F (8) P-value
Ubiquitin-dependent
Ubiquitin 100±22 117±21 102±10 106± 28 0.95
E2 100±23 a 269±53 b 190± 42 ab 194±49 ab 0.11
C8 proteasome subunit 100±23 a 224±20 b 280±58 b 235±49 b 0.035
C2 proteasome subunit 100±11 a 220±44 b 160±26 b 220±32 b 0.036
Murf-1 100±15 a 410±77 b 342±58 b 144±34 a 0.001
Atrogin-1 100±18 a 323±69 b 263±65 b 127±30 a 0.007
Lysosomal
Cathepsin B 100±12 129±61 71±15 72±18 0.54
Calcium-dependent
m-calpain 100±12 a 167±22 b 110±12 a 90± 24 a 0.052
Results are mean± standard error for the number of animals indicated in parentheses. C, animals without tumour; T+ S, tumour-bearing
rats treated with sorafenib; T+ S+ F, tumour-bearing rats treated with sorafenib and formoterol; T + S+ F+MA, tumour-bearing rats
treated with sorafenib, formoterol, and megestrol acetate. Statistical significance of the results by one-way analysis of variance (ANOVA),
following a post hoc Duncan test. Different superscripts indicate significant differences between groups.
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for the latter, consistently with the rescue of muscle mass.
Formoterol treatment alone was only able to induce an
improvement in grip strength.
The presence of a tumour induces important metabolic
changes which affect carbohydrate, lipid and protein metab-
olism.41 As readout of such alterations, tumour burden is as-
sociated with an increase in circulating lactate and a
decreased glycaemia. The combined treatment was able to
partially improve glycaemia and hyperlactemia in Sor-treated
TB animals while had no effects on either circulating albumin
or triglycerides (Figure 7).
Since one of the most deleterious events taking place in skel-
etal muscle during tumour growth is the increased protein
breakdown, we also examined the effects of either F or F with
MA treatments on gene expression of muscle proteolytic sys-
tems. As shown in Table 3, the combined treatment F+MA sig-
nificantly reduced both Murf-1 and Atrogin-1 gene expression
in gastrocnemius muscle, two Ub-ligases that represent the lim-
iting step of proteasome-dependent degradation.42 Interestingly,
the double treatment also decreasedm-calpain gene expression,
known to play a role inmuscle proteolysis in cancer cachexia.43,44
Indeed, it was suggested that calcium-dependent proteases par-
ticipate in the release of myofilaments from the sarcomere, and
these myofilaments would be later degraded by the ubiquitin-
dependent proteolytic system.45 Sandri et al. reported the role
for lysosome activity in muscle degradation during cancer ca-
chexia. Actually, activation of FoxO3 stimulates lysosomal prote-
olysis in muscle by inducing the expression of autophagy-related
genes.46 It has been recently shown that autophagy plays a rele-
vant role even in cancer cachexia.47 Consistently, both F alone or
in combination with MA effectively prevented the increase of
Cathepsin B transcript observed in TB rats.
In summary, it is important to point out that this is one of the
few studies that incorporates anti-tumour together with anti-
cachectic treatments, since the majority of the data available
from pre-clinical studies usually take into consideration only
the cachectic effect induced in a short interval by tumour
growth or by single anti-neoplastic drugs, not the combination.
Such experimental settings, however, are far from the clinical
practice, where an anti-tumour intervention is adopted as soon
as the cancer is diagnosed and chronic cachexia occurs. The
other way round, the study of drug toxicity and pharmacokinet-
ics in the absence of the tumour might hide important
aspects.48 As a consequence, the use of inappropriate pre-
clinical models complicates and limits the transfer of basic dis-
coveries from the bench to the bedside. On the contrary, in the
present study, Sor administration effectively reduced tumour
burden and prolonged survival at the cost of a dramatic
cachectic state, reflecting the clinical conditions of cancer
patients. Testing the effectiveness of candidate drugs in these
experimental conditions offers a valid and reliable approach
for translational research in the cancer cachexia field. Very re-
cent data obtained in cancer patients using a similar combina-
tion strengthen this hypothesis.22 In conclusion, the present
results reinforce the idea that a successful cachexia treatment
has to be multifactorial. From this point of view, the combina-
tion of an orexigenic drug (MA) with an anti-catabolic one (F)
resulted in clearly beneficial effects in TB animals.
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